Experience of the use of nimesulide, a cyclo-oxygenase-2 selective prostaglandin synthesis inhibitor, in the prevention of preterm labour in 44 high-risk cases
Authors:
- Katie M GroomKGKatie M Groom
- Pr BennettPBPr Bennett
- 1 April 2004
- journal article
- research article
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 24 (3) , 226-229
Abstract
We report pregnancy outcome and fetal side effects in women at high risk of second trimester loss and early preterm delivery treated with nimesulide. This was a prospective observational study of 44 women treated with nimesulide from 17 to 32 weeks. All women underwent weekly ultrasound scans for AFI, Doppler studies of the ductus arteriosus and transvaginal assessment of cervical length. Outcome data were collected. Oligohydramnios occurred in 54% of cases; this returned to normal in all cases on discontinuation of treatment. There were no cases of constriction of the ductus arteriosus. Thirty-nine women took home a live baby. The mean gestation at delivery was 33 weeks and 1 day and the mean birth weight was 2105 g. Nimesulide appeared to have a significant benefit in women at high risk of preterm delivery with no long-term harmful effects on the fetus if monitored closely with an intensive ultrasound scanning regimen. Randomised placebo controlled trials are required to assess fully the benefit of COX-2 selective and specific prostaglandin synthesis inhibitors.Keywords
This publication has 11 references indexed in Scilit:
- Cyclooxygenase-2–selective inhibitors impair glomerulogenesis and renal cortical developmentKidney International, 2000
- Nimesulide and neonatal renal failureThe Lancet, 2000
- The Roles of the Cyclo-oxygenases Types One and Two in Prostaglandin Synthesis in Human Fetal Membranes at TermPlacenta, 2000
- Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolyticThe Lancet, 1999
- Tocolytics for preterm labor: a systematic review*1Obstetrics & Gynecology, 1999
- Changes in the expression of the type‐2 but not the type‐1 cyclo‐oxygenase enzyme in chorion‐decidua with the onset of labourBJOG: An International Journal of Obstetrics & Gynaecology, 1998
- Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefitsAmerican Journal of Obstetrics and Gynecology, 1997
- Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm deliveryThe Lancet, 1997
- Expression of cyclooxygenase types 1 and 2 in human fetal membranes at termAmerican Journal of Obstetrics and Gynecology, 1995
- Neonatal Complications after the Administration of Indomethacin for Preterm LaborNew England Journal of Medicine, 1993